Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombosomes in Bleeding Thrombocytopenic Patients
NCT03394755Phase 1Completed
- Sponsor
- Cellphire Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- Aug 2019
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label trial of Thrombosomes in Thrombocytopenia (3 cohorts), sponsored by Cellphire Therapeutics, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 30 days and Treatment-Emergent Serious Adverse Events at 30 days. Started Mar 2018; status: completed.
02
Drugs
Thrombosomes
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT03394755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394755.